1. Home
  2. APLM vs ULY Comparison

APLM vs ULY Comparison

Compare APLM & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
    SELLHOLDBUYas of 7 hours ago
  • ULY
    SELLHOLDBUYas of 7 hours ago
  • Stock Information
  • Founded
  • APLM 2016
  • ULY 2013
  • Country
  • APLM United States
  • ULY United States
  • Employees
  • APLM N/A
  • ULY N/A
  • Industry
  • APLM Blank Checks
  • ULY
  • Sector
  • APLM Finance
  • ULY
  • Exchange
  • APLM Nasdaq
  • ULY Nasdaq
  • Market Cap
  • APLM 12.3M
  • ULY 6.7M
  • IPO Year
  • APLM N/A
  • ULY N/A
  • Fundamental
  • Price
  • APLM $10.67
  • ULY $0.50
  • Analyst Decision
  • APLM Strong Buy
  • ULY Strong Buy
  • Analyst Count
  • APLM 2
  • ULY 1
  • Target Price
  • APLM $425.00
  • ULY $1.50
  • AVG Volume (30 Days)
  • APLM 54.1K
  • ULY 442.2K
  • Earning Date
  • APLM 02-15-2025
  • ULY 11-12-2024
  • Dividend Yield
  • APLM N/A
  • ULY N/A
  • EPS Growth
  • APLM N/A
  • ULY N/A
  • EPS
  • APLM N/A
  • ULY 7.18
  • Revenue
  • APLM $2,101,000.00
  • ULY $155,926,000.00
  • Revenue This Year
  • APLM N/A
  • ULY N/A
  • Revenue Next Year
  • APLM N/A
  • ULY $20.40
  • P/E Ratio
  • APLM N/A
  • ULY $0.07
  • Revenue Growth
  • APLM 70.54
  • ULY N/A
  • 52 Week Low
  • APLM $6.50
  • ULY $0.41
  • 52 Week High
  • APLM $105.00
  • ULY $3.45
  • Technical
  • Relative Strength Index (RSI)
  • APLM 52.92
  • ULY 46.70
  • Support Level
  • APLM $10.15
  • ULY $0.41
  • Resistance Level
  • APLM $12.00
  • ULY $0.63
  • Average True Range (ATR)
  • APLM 1.30
  • ULY 0.08
  • MACD
  • APLM 0.21
  • ULY 0.01
  • Stochastic Oscillator
  • APLM 69.63
  • ULY 39.27

Stock Price Comparison Chart: APLM vs ULY

APLM
ULY
2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober202505101520253035APLM VS ULY

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and lead to long wait times. Urgently offers an innovative alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use